ClinicalTrials.gg

Program

Ascorbic Acid

Also written as “Vitamin C”, “PLENVU®” and “Ascorbic acid ophthalmic solution 5%”.

Its studies are mostly in Respiratory Tract Infections · Corneal Endothelial Cell Loss · Neuralgia · Pain · Carcinoma, Basal Cell, led by 8 companies.

Furthest: phase 4, since Apr 7, 201110 company-led studies, 2 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline30 open or runningphase 4since Apr 7, 2011Apr 7, 2011none ahead
Caravel Oculus Pty11 open or runningphase 2since Jul 1, 2026Jul 1, 2026Jan 2027phase 2 · NCT07694375
Center for Biomedical Research10 open or runningearly phase 1since Feb 19, 2020Feb 19, 2020none ahead
LadeRx11 open or runningphase 1since May 20, 2024May 20, 2024none ahead
Lindenhofgruppe10 open or runningphase 4since Jul 10, 2020Jul 10, 2020none ahead
McGuff Pharmaceuticals10 open or runningphase 1since Aug 24, 2015Aug 24, 2015none ahead
Pascoe Pharmazeutische Praeparate10 open or runningphase 2since Sep 27, 2022Sep 27, 2022none ahead
Spherium Biomed10 open or runningphase 2since Nov 10, 2015Nov 10, 2015none ahead

Also a collaborator on its studies: parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 7, 2011First study: phase 4 study in Influenza, HumanNew to GlaxoSmithKlineGlaxoSmithKline · NCT01332578 · 25 enrolled · United Kingdom
  2. Aug 24, 2015McGuff Pharmaceuticals's first study: phase 1 study in PharmacokineticsNew to McGuff PharmaceuticalsMcGuff Pharmaceuticals · NCT02534753 · 8 enrolled · United States
  3. Nov 10, 2015Spherium Biomed's first study: phase 2 study in Temporomandibular Joint DisordersNew to Spherium BiomedSpherium Biomed · NCT02602483 · 96 enrolled · Spain
  4. Feb 1, 20162 phase 3 studies in Respiratory Tract InfectionsGlaxoSmithKline · NCT02730364, NCT02678234
  5. Feb 19, 2020Center for Biomedical Research's first study: early phase 1 study in Carcinoma, Basal CellNew to Center for Biomedical ResearchCenter for Biomedical Research · NCT04279535 · 25 enrolled · United States
  6. Jul 10, 2020Lindenhofgruppe's first study: phase 4 study in PainNew to LindenhofgruppeLindenhofgruppe · NCT04472000 · 46 enrolled · Switzerland
  7. Sep 27, 2022Pascoe Pharmazeutische Praeparate's first study: phase 2 study in NeuralgiaNew to Pascoe Pharmazeutische PraeparatePascoe Pharmazeutische Praeparate · NCT05561257 · 12 enrolled · Germany
  8. May 20, 2024LadeRx's first study: phase 1 study in SafetyNew to LadeRxLadeRx · NCT06433791 · 12 planned · United States
  9. Jul 1, 2026Caravel Oculus Pty's first study: phase 2 study in Corneal Endothelial Cell LossNew to Caravel Oculus PtyCaravel Oculus Pty · NCT07694375 · 200 planned · Australia

Ahead

  1. Jan 2027Primary completion: phase 2 study in Corneal Endothelial Cell LossCaravel Oculus Pty · NCT07694375

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07694375Corneal Endothelial Cell Loss · Australia2RecruitingCaravel Oculus PtyJan 2027200
NCT06433791Safety · United States1By invitationLadeRxMay 17, 202512
NCT05561257Neuralgia · Germany2TerminatedPascoe Pharmazeutische PraeparateFeb 28, 202412
NCT04472000Pain · Switzerland4TerminatedLindenhofgruppeMay 16, 202346
NCT04279535Carcinoma, Basal Cell · United StatesEarly 1CompletedCenter for Biomedical ResearchMar 1, 201925
NCT02678234Respiratory Tract Infections3WithdrawnGlaxoSmithKlineApr 1, 20170
NCT02730364Respiratory Tract Infections3WithdrawnGlaxoSmithKlineApr 1, 20170
NCT02602483Temporomandibular Joint Disorders · Spain2CompletedSpherium BiomedDec 201696
NCT02534753Pharmacokinetics · United States1CompletedMcGuff PharmaceuticalsNov 20158
NCT01332578Influenza, Human · United Kingdom4CompletedGlaxoSmithKlineJun 201125

How it is read

Names in the registry

  • “Vitamin C”, 2 entries
  • “Ascorbic Acid”, 2 entries
  • “PLENVU®”, 1 entry
  • “Ascorbic acid ophthalmic solution 5%”, 1 entry
  • “Ascorbate-Meglumine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.